– USA, FL – TapImmune Inc. (OTCMKTS: TPIV), a clinical-stage immunology-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, is pleased to announce the appointment of Frederick G. Wasserman to its Board as an Independent Director.
Frederick (Rick) is an accomplished Board Director with 35 years of business experience. He has served during his career as President, COO and CFO of entrepreneurial, middle-market companies. Rick has a strong financial background which he has successfully focused on all aspects of company operations including cash flow, profitability and equity valuation. He has served as a member of Audit and Corporate Governance Committees for public companies in the U.S. and Europe. In his role as President of FGW Partners LLC, Pennington, New Jersey, he has assisted small and micro-cap companies at transitional points in their evolutions. This has included focus on corporate governance, investment analysis and liquidity management, as well as general financial and operational issues.
Rick was a Certified Public Accountant who held staff positions through Audit Manager for three accounting firms. He has a B.S. in Economics from the Wharton School, University of Pennsylvania, PA.
Dr. Glynn Wilson, Chairman & CEO of TapImmune, stated, “We welcome Rick to the TapImmune Board of Directors. His strong financial background and success in working as an Officer or as a Board member of a variety of entrepreneurial public companies will be a significant asset to TapImmune in the next phase of our Company’s growth”.
About TapImmune Inc.
TapImmune Inc. is an immune-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastatic disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.